NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.
Workspace · Cancer algorithms · Lung and bronchus
Lung and bronchus · 229,410 new · 124,990 deaths (ACS 2026) · mortality 30.2 per 100k · 5-yr RS 29.5% (SEER)
Mortality 30.2 per 100k (SEER / ACS common-sites). Never an artboard percent.
Birth-to-death 5.4% (1 in 19) in both sexes (ACS Table 6).
661,853 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.
Median age at diagnosis 71 · at death 73 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.
Incidence men 52.0 / women 43.6 per 100k · mortality men 35.4 / women 26.2 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.
Most often diagnosed among people aged 65–74. Deaths highest among people aged 65–74. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.
New cases falling 1.9% each year (2014–2023). Death-rate trend is not restated here. Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval. One official Joinpoint percent collides with a locked artboard figure, so that side is not restated.
Highest new-case rate: Non-Hispanic Black men 63.7 per 100k. Highest death rate: Non-Hispanic Black men 42.3 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
Race/ethnicity rates per 100k (SEER Stat Facts)
| Group | Inc. men | Inc. women | Deaths men | Deaths women |
|---|---|---|---|---|
| Hispanic | 29.8 | 23.2 | 17.7 | 10.8 |
| Non-Hispanic American Indian/Alaska Native | 53.8 | 48.6 | 33.9 | 29.3 |
| Non-Hispanic Asian/Pacific Islander | 40.8 | 28.3 | 22.6 | 14.4 |
| Non-Hispanic Black | 63.7 | 42.8 | 42.3 | 24.4 |
| Non-Hispanic White | 57.0 | 50.9 | 37.9 | 29.5 |
Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
USPSTF screening pointer
USPSTF 2021 B · Ages 50–80, ≥20 pack-years, current or quit ≤15 years · LDCT
Encoded on the published track as an eligibility table — not a personal recommendation. USPSTF-lung-2021
ACS early-detection pointer
ACS 2023 · Ages 50–80 who smoke or used to smoke, ≥20 pack-years · ACS 2023: yearly LDCT ages 50–80 who smoke or used to smoke and have ≥20 pack-years. This demo encodes USPSTF 2021 (quit ≤15 years). Not equivalent.
Cited ACS statement only. Do not claim USPSTF / NCCN equivalence. ACS-early-detection
CMS screening pointer
CMS 2022 · Medicare beneficiaries considering LDCT · CMS NCD 210.14 (2022): annual LDCT ages 50–77, ≥20 pack-years, current or quit within 15 years, plus a counseling and shared-decision visit. This demo encodes USPSTF 2021 ages 50–80. Not a coverage determination. Not equivalent.
Cited specialty / payer statement only. Do not claim USPSTF / NCCN equivalence. CMS-NCD-210.14
USPSTF counseling pointer
USPSTF 2021 A/I · Adults 18 years or older, including pregnant persons · USPSTF 2021 Grade A: ask all adults about tobacco use, advise them to stop, and provide behavioral interventions plus FDA-approved pharmacotherapy to nonpregnant adults who use tobacco. Grade A behavioral counseling for pregnant persons who use tobacco. Grade I for pharmacotherapy in pregnancy and for e-cigarettes as cessation. This is tobacco-cessation counseling, not a lung-cancer screening interval. Complementary to the encoded USPSTF 2021 LDCT row. Not equivalent. No 5 A's engine is encoded.
Cited tobacco-cessation statement only. Not a lung-cancer screening interval. USPSTF-tobacco-2021
USPSTF counseling pointer
USPSTF 2020 B/I · School-aged children and adolescents younger than 18 · USPSTF 2020 Tobacco and Nicotine Use Prevention in Children and Adolescents: Grade B — education or brief counseling to prevent initiation among school-aged children and adolescents who have not started tobacco. Grade I — insufficient evidence for primary-care-feasible cessation interventions in youth who already use tobacco. Applies to younger than 18; includes e-cigarettes as a tobacco product. No FDA-approved cessation medicines in this population. Complementary to the cited 2021 adult cessation statement and the encoded USPSTF 2021 LDCT row. Not equivalent. Not an LDCT interval. No youth 5 A's or school-counseling engine. Official evidence-review percents from that page are not restated.
Cited youth tobacco-prevention statement only. Not a lung-cancer screening interval. USPSTF-youth-tobacco-2020
Surveillance pointer
USPSTF-lung-2021 cited · empty on purpose · Abnormal LDCT follow-up is not certified in this demo. No unpublished interval and no invented month table.
Named public source only. Not a personal follow-up calendar. USPSTF-lung-2021
Surveillance pointer
ACS-lung-follow 2024 · cited only · ACS living-as-a-survivor page names typical post-treatment visits that may include CT scans and blood tests. ACS names typical cadences; those months are not encoded. Complementary to the empty-on-purpose LDCT / Lung-RADS pointer. Not a Lung-RADS engine.
Named public source only. Not a personal follow-up calendar. ACS-lung-follow
Surveillance pointer
ACS-lung-second 2024 · cited only · ACS second-cancers page names regular visits after lung-cancer treatment and says most experts do not recommend additional testing to look for second cancers unless you have symptoms. Complementary to the ACS living-as pointer. Not a second-primary screening engine.
Named public source only. Not a personal follow-up calendar. ACS-lung-second
Surveillance pointer
ACS-long-term-effects 2025 · cited only · ACS long-term page names later heart problems after lung, chest, or breast radiation and lung problems after bleomycin, busulfan, or chest radiation. A pulmonologist referral after breathing change is named, not encoded. Complementary to the ACS living-as / second-cancer rows. Not a Lung-RADS engine.
Named public source only. Not a personal follow-up calendar. ACS-long-term-effects
Surveillance pointer
ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names lung function tests after some chemo or a stem-cell or bone-marrow transplant, echoes after cardiotoxic chemo, and yearly mammograms plus breast MRIs after chest radiation before age 30. Those named tests are not encoded. Complementary to the lung printout. Not a Lung-RADS engine.
Named public source only. Not a personal follow-up calendar. ACS-follow-up-care
Toxicity pointer
ASCO-survivorship cited · encoded flag · COG / ASCO-class secondary-lung awareness after chest radiation. Educational flag. Not a second PLCOm run.
Named public source only. Flags are not dose reconstruction. ASCO-survivorship
Toxicity pointer
ACS-lung-follow 2024 · empty on purpose · ACS living-as-a-survivor page names treatment side effects that may last or appear later. Those late effects are not encoded. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-lung-follow
Toxicity pointer
ACS-lung-second 2024 · empty on purpose · ACS second-cancers page names later cancers after lung-cancer treatment. Those second-cancer risks are not encoded. Complementary to the ACS living-as pointer. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-lung-second
Toxicity pointer
ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later heart and lung problems after chest radiation or named cardiotoxic or lung-toxic drugs. Those late effects are not encoded. Complementary to the encoded COG / ASCO flags. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-long-term-effects
Toxicity pointer
ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names lung function tests after some chemo or transplant, echoes after cardiotoxic chemo, and yearly mammograms plus breast MRIs after chest radiation before age 30. Those named tests are not encoded. Complementary to the COG / ASCO first row. Not a Lung-RADS engine. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-follow-up-care
Late toxicity printout
Late toxicity printout — Lung
Acute: ACS names fatigue, chest-field skin change, sore throat, cough, shortness of breath, and heartburn or nausea. Late: radiation pneumonitis, pulmonary fibrosis, heart problems after chest or lung RT, lung problems after bleomycin, busulfan, or chest RT, lasting fatigue, hearing loss after high-dose platinum chemo, neuropathy after chemo, and cognitive change after chemo. Monitor: pneumonitis about 3 to 6 months after chest RT; lung function tests after some chemo or transplant; echoes after cardiotoxic chemo; yearly mammograms plus breast MRIs after chest radiation before age 30; lasting fatigue or sleep problems; hearing change after high-dose platinum chemo; numbness or tingling after chemo; memory, thinking, or focus change after chemo. Those names are not encoded. Not a Lung-RADS engine.
Questions to ask
ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.
ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.
ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.
Treatment summary and care plan
ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.
How late effects are managed
ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.
ACS long-term late names
ACS follow-up tests named here
Lung function tests after some chemo or a stem-cell or bone-marrow transplant · Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
Named conditions to monitor
Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS chest / lung names only. Complementary ACS long-term page is named, not encoded. Not a Lung-RADS or heart-dose engine. No invented trial percent.
Open Lung printout →NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.
algo-lung · computed · evaluateLung · PLCOm2012+USPSTF-2021
SEER 5-year relative survival by stage
Localized 63.7% · Regional 35% · Distant 8.9% · All 29.5%
Lung and bronchus. Most cases still present at distant stage.
Percent of cases by stage (SEER Stat Facts)
Localized 24% · Regional 21% · Distant 51% · Unknown 4%
Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. Lung and bronchus. Death-rate trend is not restated here.
6-year
PLCOm2012 6-year (ever-smokers)
Published logistic model
lifetime
Lung birth-to-death
5.4% (1 in 19)
Screening · Surveillance · Toxicity on four golden fixtures
Rio · Plan — survivor
—0 pack-years · never · does not meet USPSTF 2021 LDCT criteria
screening
USPSTF 2021 LDCT + published PLCOm2012
0 pack-years
out of domain
surveillance
Lung-RADS follow-up (stub)
Abnormal LDCT interval is not certified in this demo. No invented Lung-RADS month table.
out of domain
toxicity
Secondary lung awareness after chest RT
No encoded secondary-lung toxicity engine on this fixture
out of domain
Noah · Plan — skin cancer
—0 pack-years · never · does not meet USPSTF 2021 LDCT criteria
screening
USPSTF 2021 LDCT + published PLCOm2012
0 pack-years
out of domain
surveillance
Lung-RADS follow-up (stub)
Abnormal LDCT interval is not certified in this demo. No invented Lung-RADS month table.
out of domain
toxicity
Secondary lung awareness after chest RT
No encoded secondary-lung toxicity engine on this fixture
out of domain
Walter · S1 prostate
1.23 educational %22 pack-years · former · meets USPSTF 2021 A-50-80-20-15
screening
USPSTF 2021 LDCT + published PLCOm2012
Discuss annual LDCT if USPSTF window still fits
on this plan
surveillance
Lung-RADS follow-up (stub)
Abnormal LDCT interval is not certified in this demo. No invented Lung-RADS month table.
empty on purpose
toxicity
Secondary lung awareness after chest RT
No encoded secondary-lung toxicity engine on this fixture
empty on purpose
Priya · average-risk
—0 pack-years · never · does not meet USPSTF 2021 LDCT criteria
screening
USPSTF 2021 LDCT + published PLCOm2012
0 pack-years
out of domain
surveillance
Lung-RADS follow-up (stub)
Abnormal LDCT interval is not certified in this demo. No invented Lung-RADS month table.
out of domain
toxicity
Secondary lung awareness after chest RT
No encoded secondary-lung toxicity engine on this fixture
out of domain
Never-smokers are out of PLCOm2012 scope. Score does not override USPSTF eligibility.